These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23928902)

  • 1. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.
    Yang LP
    Drugs; 2013 Aug; 73(12):1357-66. PubMed ID: 23928902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
    Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M
    Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
    Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
    MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.
    Izikson R; Leffell DJ; Bock SA; Patriarca PA; Post P; Dunkle LM; Cox MM
    Vaccine; 2015 Nov; 33(48):6622-8. PubMed ID: 26529070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.
    Cox MM; Izikson R; Post P; Dunkle L
    Ther Adv Vaccines; 2015 Jul; 3(4):97-108. PubMed ID: 26478817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
    O Murchu E; Comber L; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Ryan M; Teljeur C; Carnahan A; Pérez JJ; Robertson AH; Johansen K; Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P
    Rev Med Virol; 2023 May; 33(3):e2331. PubMed ID: 35106885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.
    Carter NJ; Curran MP
    Drugs; 2011 Aug; 71(12):1591-622. PubMed ID: 21861544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.
    Grohskopf LA; Alyanak E; Broder KR; Blanton LH; Fry AM; Jernigan DB; Atmar RL
    MMWR Recomm Rep; 2020 Aug; 69(8):1-24. PubMed ID: 32820746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
    J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FluBlok, a recombinant hemagglutinin influenza vaccine.
    Cox MM; Patriarca PA; Treanor J
    Influenza Other Respir Viruses; 2008 Nov; 2(6):211-9. PubMed ID: 19453397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.
    Jackson LA; Gaglani MJ; Keyserling HL; Balser J; Bouveret N; Fries L; Treanor JJ
    BMC Infect Dis; 2010 Mar; 10():71. PubMed ID: 20236548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
    Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccine for 2021-2022.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):153-157. PubMed ID: 34550956
    [No Abstract]   [Full Text] [Related]  

  • 18. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and Control of Seasonal Influenza with Vaccines.
    Grohskopf LA; Sokolow LZ; Broder KR; Olsen SJ; Karron RA; Jernigan DB; Bresee JS
    MMWR Recomm Rep; 2016 Aug; 65(5):1-54. PubMed ID: 27560619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.